3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one | 126645-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one
• 英文别名: 3-<(tert-butyldimethylsilyl)oxy>-2-pyrrolidinone；3-(tert-Butyldimethylsilyloxy)pyrrolidin-2-one；3-[tert-butyl(dimethyl)silyl]oxypyrrolidin-2-one
• CAS: 126645-95-2
• 化学式: C₁₀H₂₁NO₂Si
• 分子量: 215.368
• InChiKey: QEJCHYKXNFQQSM-UHFFFAOYSA-N

物化性质

• 熔点：
  77-78 °C
• 沸点：
  290.0±33.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one 在 三乙胺 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 1.5h， 生成 4-<(tert-butyldimethylsilyl)oxy>-3,4-dihydro-5-methyl-2H-pyrrole
  参考文献：
  名称：

  Selective nucleophilic addition reactions of alkyllithium reagents with N-(trimethylsilyl)lactams. Synthesis of cyclic ketimines

  摘要：

  DOI：

  10.1021/jo00298a062
• 作为产物：
  描述：

  3-羟基-2-吡咯烷酮 生成 3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one
  参考文献：
  名称：

  Synthesis of (−)-8-deoxy-7-hydroxy-swainsonine and (±)-6,8-dideoxy-castanospermine

  摘要：

  A total synthesis of (1S,2R,7S,8aR)-1,2,7-trihydroxyindolizidine 3 has been achieved in few steps from lactam 4. The dihydroxyderivative 14 has also been PrePared with the same general synthetic approach adapting a Michael addition and a thioamide-diazoketone cyclocondensation as key steps.

  DOI：

  10.1016/s0040-4039(00)79036-8

文献信息

• [EN] HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DU RÉCEPTEUR DU CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2015161014A1

  公开（公告）日：2015-10-22

  The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及杂环化合物，其是CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的这类疾病中使用这些化合物和组合物。
• Synthesis of Optically Active Vasicinone Based on Intramolecular Aza-Wittig Reaction and Asymmetric Oxidation¹
  作者：Shoji Eguchi、Toshio Suzuki、Tomohiro Okawa、Yuji Matsushita、Eiji Yashima、Yoshio Okamoto

  DOI：10.1021/jo9609283

  日期：1996.1.1

  deoxyvasicinone was treated with (S)-(+)-reagent to afford (R)-(+)-vasicinone in 71% ee, while the reaction with (R)-(-)-reagent gave (S)-(-)-vasicinone in 62% ee. The optical purity was analyzed by HPLC on specially modified cellulose as a stationary phase. These results provided a facile method to prepare both optical isomers of vasicinone and confirmed the recently reversed stereochemistry of natural (-)-vasicinone

  通过两种不同的方法合成了喹唑啉生物碱的两种光学异构体：vasicinone。第一种方法使用（3S）-3-羟基-γ-内酰胺作为手性合成子，在O-TBDMS保护后，将邻叠氮基苯甲酰化，然后用三正丁基膦处理，得到（S）-（-） -vasicinone通过串联的Staudinger /分子内aza-Wittig反应。第二种方法分别用（1S）-（+）-或（1R）-（-）-（10-樟脑磺酰基）恶唑烷（Davis试剂）对脱氧西西酮进行不对称氧化。用（S）-（+）-试剂处理脱氧vasinin的氮杂-烯酸酯阴离子，得到71％ee的（R）-（+）-vasicinone，而与（R）-（-）-试剂的反应得到（ S）-（-）-vasininone在62％ee中。通过HPLC在专门改性的纤维素上作为固定相分析光学纯度。
• Cephalosporin antibiotics
  申请人：Hoffmann-La Roche Inc.

  公开号：US05523400A1

  公开（公告）日：1996-06-04

  The present invention relates to compounds of the formula ##STR1## wherein R.sup.1 is an acyl group derived from a carboxylic acid, hydrogen, or an amino protecting group; R.sup.2 is hydrogen, hydroxy, lower alkyl-Q.sub.p -, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl-Q.sub.p -, aryl-Q.sub.p -, aryloxy, aralkoxy or a heterocyclic ring, the lower alkyl, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl, aryl, aryloxy, aralkoxy and the heterocyclic ring being unsubstituted or substituted with at least one group selected from carboxy, amino, nitro, oxo, cycloalkyl, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, --CONR.sup.4 R.sup.5, --N(R.sup.5)COOR.sup.9, R.sup.5 CO--, R.sup.5 OCO-- or R.sup.5 COO-- where R.sup.4 is hydrogen, lower alkyl, or cycloalkyl; R.sup.5 is hydrogen or lower alkyl; R.sup.9 is lower alkyl, lower alkenyl or a carboxylic acid protecting group; Q is --CO-- or --SO.sub.2 --; m is 0 or 1; n is 0, 1 or 2; p is 0 or 1; as well as readily hydrolyzable esters thereof, pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their esters and salts. The compounds are useful as oral or parenteral antibiotics against a broad spectrum of organisms.

  本发明涉及以下式的化合物：其中 R.sup.1 是从羧酸、氢或氨基保护基衍生的酰基；R.sup.2 是氢、羟基、较低烷基-Q.sub.p-、环烷基、较低烷氧基、较低烯基、环烯基、较低炔基、芳基烷基-Q.sub.p-、芳基-Q.sub.p-、芳氧基、芳基烷氧基或杂环环，其中较低烷基、环烷基、较低烷氧基、较低烯基、环烯基、较低炔基、芳基烷基、芳基、芳氧基、芳基烷氧基和杂环环未取代或取代至少一个羧基、氨基、硝基、氧代、环烷基、氰基、较低烷基、较低烷氧基、羟基、卤素、--CONR.sup.4R.sup.5、--N(R.sup.5)COOR.sup.9、R.sup.5CO--、R.sup.5OCO--或R.sup.5COO--中选择的至少一个基团；其中 R.sup.4 是氢、较低烷基或环烷基；R.sup.5 是氢或较低烷基；R.sup.9 是较低烷基、较低烯基或羧酸保护基；Q 是--CO--或--SO.sub.2--；m 为 0 或 1；n 为 0、1 或 2；p 为 0 或 1；以及这些化合物的易水解酯、药用上可接受的盐以及公式 I 中的化合物及其酯和盐的水合物。这些化合物可用作口服或静脉注射抗生素，对广谱生物有作用。
• Aryloxy-Substituted Benzimidazole Derivatives
  申请人：Hashimoto Noriaki

  公开号：US20080125429A1

  公开（公告）日：2008-05-29

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R 1 and R 2 represent a hydrogen, etc.; R 3 represents a hydrogen atom, a halogen atom, etc.; R 4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R 5 and R 6 each represent a hydrogen atom, a lower alkyl group, etc.; X 1 , X 2 , X 3 and X 4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X 1 to X 4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及用于糖尿病的治疗和/或预防，或用于糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化等的治疗和/或预防，以及用于肥胖症的治疗和/或预防。本发明涉及一种化合物的公式(I)：[其中R1和R2分别表示氢等；R3表示氢原子、卤原子等；R4各自独立地表示氢原子、低级烷基等；Q表示碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自表示氢原子、低级烷基等；X1、X2、X3和X4各自独立地表示碳原子或氮原子；Z表示氧原子、硫原子或氮原子；Ar表示芳基或杂环芳基，可选择性地单取代至三取代于β取代基；环A表示一个含氮的5-或6成员杂芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（前提是X1至X4中至少有两个是碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，并且可用作糖尿病的治疗。
• Aryloxy-substituted benzimidazole derivatives
  申请人：MSD K.K.

  公开号：US07932394B2

  公开（公告）日：2011-04-26

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X1 to X4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及一种治疗和/或预防糖尿病，或一种治疗和/或预防糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化，以及进一步治疗和/或预防肥胖症的药物。本发明涉及公式(I)的化合物：[其中R1和R2代表氢等；R3代表氢原子、卤原子等；R4各自独立地代表氢原子、较低的烷基等；Q代表碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自代表氢原子、较低的烷基等；X1、X2、X3和X4各自独立地代表碳原子或氮原子；Z代表氧原子、硫原子或氮原子；Ar代表芳基或杂环芳基，可选择性地单取代至三取代于从取代基β选择的基团；环A代表一含有5-或6-成员的含氮杂环芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（但至少X1至X4中的两个为碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，可用于治疗糖尿病。